Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
04/30/2009
Trade Name:
Axert
Generic or Proper Name (*):
almotriptan
Indications Studied:
Acute treatment of pediatric migraine in adolescent patients age 12-17 years
Therapeutic Category:
Antimigraine
Ages Studied:
12-17 years
Study #:
1
Study Type:
Efficacy
Study Design:
Single-Blind/Placebo/Parallel Group
No Patients:
714
No Centers:
93
No Countries:
4
BPCA(B), PREA(P):
B
Asian:
2
Black:
121
Other:
28
White:
539
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
18
Hispanic/Latino:
179
Non-Hispanic/Non Latino:
531
-
-